HOME >> BIOLOGY >> NEWS
Study: breath test effective in showing patients who should get less cancer drug

Battling cancer is traumatic enough without worrying about whether chemotherapy will prove toxic, but that's the added risk facing a minority of cancer patients.

Standard doses of chemotherapy -- often effective in treating various solid tumors -- sometimes kill people whose livers cannot clear the drug at the normal rate. Doctors can't tell beforehand which patients might have trouble with the treatment.

Now, a new study shows a relatively simple technique pioneered by a University of North Carolina at Chapel Hill, physician can distinguish between patients who metabolize one anti-cancer drug normally and those who need to receive lower doses for safety. Researchers say the approach might work for other chemotherapy agents and perhaps other non-cancer drug treatments as well.

"When you take a drug like aspirin or Tylenol, the reason you need to take it again in four to six hours is that your body has chewed it up and gotten rid of it through a certain chemical pathway in the liver," said Dr. Paul B. Watkins, professor of medicine and director of the Verne S. Caviness General Clinical Research Center at the UNC-CH School of Medicine. "Because of diet, genetics and other factors, some people just metabolize drugs a lot more slowly. As a result, the recommended dose of many chemotherapies will predictably make about 10 percent of patients very ill, and 1 or 2 percent of patients may die as a direct result of the treatment."

Conversely, patients whose livers clear a given chemotherapy rapidly may not get a dose strong enough to be effective against their cancer, he said.

A report on the new study appears in the April issue of Clinical Cancer Research, a medical journal that has just been released. Besides Watkins, authors include Drs. JoAnn Hirth, Myla Strawerman, Anne Schott and Laurence Baker of the University of Michigan.

Investigators took blood samples from 21 cancer patients several times over 24 hours to determine how fast t
'"/>

Contact: David Williamson
david_williamson@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
23-Apr-2000


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study: A little help from friends makes wounds heal faster
3. Study: Mothers turn fearless when peptide level drops
4. Study: Artificial sweetener may disrupt bodys ability to count calories
5. Study: Mimicking viruses may provide new way to defeat them
6. Study: Stroke victims may retain continuous motion ability
7. Study: Adults maintain significant improvement in ADHD with long-term use of amphetamine
8. Study: Prenatal screening in Haiti region cut syphilis by 75 percent
9. Study: Isoflavone-enriched soy proteins fail to increase bone mineral density in young women
10. Study: Genome-wide scanning unravels complex birth defect
11. Study: Higher energy intake, obesity affects all age groups, not just youths

Post Your Comments:
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 ... open architecture blade-based and rackmount computing infrastructure, today ... K80 dual-GPU accelerator throughout its GPU-enabled blade server ... of the company’s latest proprietary 80-lane Gen3 PCIe ... discrete NVIDIA Tesla K80 dual-GPU accelerator cards in ...
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Provider™ solution ... Consummate Provider™ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
Cached News: